Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

<p>Patient demographics and tumor characteristics at baseline and at surgery, by randomized treatment group.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Nigel Bundred (15046233) (author)
Andere auteurs:	Nuria Porta (15029895) (author), Adrian Murray Brunt (15046236) (author), Angela Cramer (5870894) (author), Andrew Hanby (25460) (author), Abeer M. Shaaban (15046239) (author), Emad A. Rakha (7957955) (author), Anne Armstrong (15045410) (author), Ramsey I. Cutress (15046242) (author), David Dodwell (15046245) (author), Marie A. Emson (15046248) (author), Abigail Evans (7421527) (author), Sue M. Hartup (15046251) (author), Kieran Horgan (15030513) (author), Sarah E. Miller (15046254) (author), Stuart A. McIntosh (11368948) (author), James P. Morden (7594370) (author), Jay Naik (15046257) (author), Sankaran Narayanan (15046260) (author), Jane Ooi (15046263) (author), Anthony I. Skene (15046266) (author), David A. Cameron (6277425) (author), Judith M. Bliss (8827107) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Breast Cancer Clinical Trial Results Phase II clinical trials Precision Medicine
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
door: Ruiyun Zhang (17142498)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Table S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
door: Nam Q. Bui (14958210)
Gepubliceerd in: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
door: Laura Boucai (15054310)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
door: Ulka N. Vaishampayan (15051039)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
door: Ulka N. Vaishampayan (15051039)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n79eqmqddmijimqp3gbo4856s9